Alector (ALEC) said Thursday it has completed enrollment for PROGRESS-AD, a 76-week phase 2 trial assessing the safety and effectiveness of AL101/GSK4527226 in slowing early-stage Alzheimer's disease progression.
Alector and GSK (GSK) are co-developing AL101, an investigational monoclonal antibody targeting the sortilin receptor to increase brain progranulin levels, currently being evaluated in PROGRESS-AD, a global, randomized, double-blind, placebo-controlled phase 2 trial led by GSK.
The trial is evaluating two dose levels of AL101, with participants randomized to receive either the drug or a placebo intravenously, and its primary endpoint is disease progression measured by the Clinical Dementia Rating Sum of Boxes, a validated tool for assessing cognitive decline, the biotechnology company said.
Shares of Alector were down 1.9% in recent Thursday trading, while GSK's were up 1%.
Price: 0.96, Change: -0.02, Percent Change: -1.87
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.